Skye Bioscience, Inc.
SKYEHealthcare|Biotechnology|US
$0.99
-0.05 (-4.78%)
DCF Value
$0.79
Cash / Share
$2.03
About
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Stock Price
-91.9%(1Y)
1M
-41.1%
3M
-76.2%
6M
-85.6%
YTD
-83.5%
1Y
-91.3%
3Y
-93.1%
5Y
-99.4%
Pipeline Summary
8 total trials0
Phase 1
2
Phase 2
0
Phase 3
2
Phase 4
Completed: 2Active: 1Unknown: 1Recruiting: 3Not Yet Recruiting: 1
Active Trials (4)
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090Obesity
Phase 2Active
Enrollment: 136 participants
Prospective Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft Active Matrix (AM) vs. Standard of Care in Arthroscopic Rotator Cuff Repair
NCT05894265Rotator Cuff Tears
N/ARecruiting
Enrollment: 72 participants
Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone
NCT06764953Venous Leg Ulcers
N/ARecruiting
Enrollment: 100 participants
Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care
NCT06767501Diabetic Foot Ulcers (DFUs)
N/ARecruiting
Enrollment: 100 participants
Key Facts
Market Cap$4.4M
Employees12 (-25% YoY)
CEOPunit Dhillon
IPO DateJan 6, 2015
Beta3.15
52-Week Range$0.98 – $12.72
Avg Volume287,805
ExchangeNASDAQ
Websiteskyebioscience.com
Ownership
Float67.2%
Shares Outstanding4.4M
Recent Insider Trades
Schwab Andrew J.SELL
Sep 22, 202627,612 shares @ $1.65
Schwab Andrew J.SELL
Sep 22, 20261,088 shares @ $1.65
Schwab Andrew J.SELL
Sep 23, 20264,528 shares @ $1.61
5AM Partners VII, LLCSELL
Sep 22, 202627,612 shares @ $1.65
5AM Partners VII, LLCSELL
Sep 22, 20261,088 shares @ $1.65
Peers
Recent News
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Sep 20, 2026 · defenseworld.net
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Sep 20, 2026 · defenseworld.net
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics
Aug 19, 2026 · defenseworld.net
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Aug 14, 2026 · seekingalpha.com
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Aug 14, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:34 AM